These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31361026)

  • 1. Decline of programmed death-1-positive circulating T regulatory cells predicts more favourable clinical outcome of patients with melanoma under immune checkpoint blockade.
    Gambichler T; Schröter U; Höxtermann S; Susok L; Stockfleth E; Becker JC
    Br J Dermatol; 2020 May; 182(5):1214-1220. PubMed ID: 31361026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Brief Communication on Circulating PD-1-positive T-Regulatory Lymphocytes in Melanoma Patients Undergoing Adjuvant Immunotherapy With Nivolumab.
    Gambichler T; Schröter U; Höxtermann S; Susok L; Stockfleth E; Becker JC
    J Immunother; 2019 Sep; 42(7):265-268. PubMed ID: 31145230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma.
    Woods DM; Ramakrishnan R; Laino AS; Berglund A; Walton K; Betts BC; Weber JS
    Clin Cancer Res; 2018 Dec; 24(24):6236-6247. PubMed ID: 30131384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade.
    Bochem J; Zelba H; Amaral T; Spreuer J; Soffel D; Eigentler T; Wagner NB; Uslu U; Terheyden P; Meier F; Garbe C; Pawelec G; Weide B; Wistuba-Hamprecht K
    PLoS One; 2019; 14(8):e0221301. PubMed ID: 31419253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti-PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients.
    Denize T; Jegede OA; Matar S; El Ahmar N; West DJ; Walton E; Bagheri AS; Savla V; Nabil Laimon Y; Gupta S; Vemula SV; Braun DA; Burke KP; Catalano PJ; Freeman GJ; Motzer RJ; Atkins MB; McDermott DF; Sharpe AH; Choueiri TK; Signoretti S
    Clin Cancer Res; 2024 Feb; 30(4):803-813. PubMed ID: 38060202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients.
    Capone M; Fratangelo F; Giannarelli D; Sorrentino C; Turiello R; Zanotta S; Galati D; Madonna G; Tuffanelli M; Scarpato L; Grimaldi AM; Esposito A; Azzaro R; Pinto A; Cavalcanti E; Pinto A; Morello S; Ascierto PA
    J Transl Med; 2020 Mar; 18(1):121. PubMed ID: 32160899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting anti-PD-1 responders in malignant melanoma from the frequency of S100A9+ monocytes in the blood.
    Rad Pour S; Pico de Coaña Y; Demorentin XM; Melief J; Thimma M; Wolodarski M; Gomez-Cabrero D; Hansson J; Kiessling R; Tegner J
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma.
    Saito R; Sawada Y; Nakamura M
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
    Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
    Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1 Upregulation Is Associated with Exhaustion of Regulatory T Cells and Reflects Immune Activation in HIV-1-Infected Individuals.
    Xiao J; Zhang L; Dong Y; Liu X; Peng L; Yang Y; Wang Y
    AIDS Res Hum Retroviruses; 2019 May; 35(5):444-452. PubMed ID: 30618263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential clinical implications of CD4
    Galati D; Zanotta S; Capone M; Madonna G; Mallardo D; Romanelli M; Simeone E; Festino L; Sparano F; Azzaro R; De Filippi R; Pinto A; Paulos CM; Ascierto PA
    J Transl Med; 2023 May; 21(1):318. PubMed ID: 37170241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma.
    Takeuchi Y; Tanemura A; Tada Y; Katayama I; Kumanogoh A; Nishikawa H
    Int Immunol; 2018 Feb; 30(1):13-22. PubMed ID: 29294043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Significance of Negative Costimulatory Molecule PD-1/PD-L1 on Peripheral Blood Regulatory T Cell Levels among Patients with Pulmonary Tuberculosis.
    Yang C; Dai F; Pulati R; Jiao Y; Xu Q
    J Trop Med; 2022; 2022():7526501. PubMed ID: 36035072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience.
    Vitale G; Lamberti G; Comito F; Di Nunno V; Massari F; Morelli MC; Ardizzoni A; Gelsomino F
    Expert Opin Biol Ther; 2020 Sep; 20(9):1047-1059. PubMed ID: 32425081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma.
    Kubo Y; Fukushima S; Inamori Y; Tsuruta M; Egashira S; Yamada-Kanazawa S; Nakahara S; Tokuzumi A; Miyashita A; Aoi J; Kajihara I; Tomita Y; Wakamatsu K; Jinnin M; Ihn H
    J Dermatol Sci; 2019 Jan; 93(1):33-40. PubMed ID: 30318169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma.
    Zhao JJ; Wen XZ; Ding Y; Li DD; Zhu BY; Li JJ; Weng DS; Zhang X; Zhang XS
    Aging (Albany NY); 2020 Jun; 12(11):10663-10675. PubMed ID: 32516130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
    Weber JS; Postow M; Lao CD; Schadendorf D
    Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.